Premier Biomedical Inc
Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. It offers pain management products comprising pain relief patch of hemp oil extracts; water-based and oil-based roll-on applicators; oil-based pump spray applicators; and ointments through its Website painreliefmeds.com and various distributors… Read more
Premier Biomedical Inc (BIEI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2023: 0.018x
Based on the latest financial reports, Premier Biomedical Inc (BIEI) has a cash flow conversion efficiency ratio of 0.018x as of December 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.82K) by net assets ($-2.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Premier Biomedical Inc - Cash Flow Conversion Efficiency Trend (2011–2023)
This chart illustrates how Premier Biomedical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Premier Biomedical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Premier Biomedical Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cartica Acquisition Corp Warrant
NASDAQ:CITEW
|
-0.008x |
|
Sylla Gold Corp.
PINK:SYGCF
|
0.000x |
|
Joshua Gold Resources Inc
PINK:JSHG
|
-0.004x |
|
Windtree Therapeutics Inc
NASDAQ:WINT
|
0.549x |
|
Fbec Worldwide
PINK:FBEC
|
0.002x |
|
Colibri Resource Corporation
PINK:CRUCF
|
-0.004x |
|
NuGene International Inc
PINK:NUGN
|
0.001x |
|
Cyon Exploration Ltd
PINK:CYNXF
|
0.066x |
Annual Cash Flow Conversion Efficiency for Premier Biomedical Inc (2011–2023)
The table below shows the annual cash flow conversion efficiency of Premier Biomedical Inc from 2011 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-2.48 Million | $-170.99K | 0.069x | +5453.27% |
| 2022-12-31 | $-2.28 Million | $2.93K | -0.001x | -157.88% |
| 2021-12-31 | $-2.25 Million | $-5.00K | 0.002x | -93.08% |
| 2020-12-31 | $-2.22 Million | $-71.20K | 0.032x | -82.88% |
| 2019-12-31 | $-1.83 Million | $-344.18K | 0.188x | -9.36% |
| 2018-12-31 | $-2.15 Million | $-444.88K | 0.207x | +6.66% |
| 2017-12-31 | $-2.61 Million | $-507.12K | 0.194x | -73.46% |
| 2016-12-31 | $-660.70K | $-483.62K | 0.732x | -32.61% |
| 2015-12-31 | $-425.56K | $-462.23K | 1.086x | -88.48% |
| 2014-12-31 | $-67.76K | $-639.08K | 9.432x | +448.50% |
| 2013-12-31 | $-249.01K | $-428.19K | 1.720x | +2.91% |
| 2012-12-31 | $-75.77K | $-126.59K | 1.671x | +153.71% |
| 2011-12-31 | $30.22K | $-94.02K | -3.111x | -- |